Novel DNA methylome biomarkers associated with adalimumab response in rheumatoid arthritis patients

Rheumatoid arthritis (RA) patients are currently treated with biological agents mostly aimed at cytokine blockade, such as tumor necrosis factor-alpha (TNFα). Currently, there are no biomarkers to predict therapy response to these agents. Here, we aimed to predict response to adalimumab (ADA) treatm...

Full description

Saved in:

Bibliographic Details
Published in:	Frontiers in immunology Vol. 14; p. 1303231
Main Authors:	Hageman, Ishtu, Mol, Femke, Atiqi, Sadaf, Joustra, Vincent, Sengul, Hilal, Henneman, Peter, Visman, Ingrid, Hakvoort, Theodorus, Nurmohamed, Mike, Wolbink, Gertjan, Levin, Evgeni, Li Yim, Andrew Y.F., D’Haens, Geert, de Jonge, Wouter J.
Format:	Journal Article
Language:	English
Published:	Switzerland Frontiers Media S.A 22.12.2023
Subjects:	adalimumab Adalimumab - therapeutic use Arthritis, Rheumatoid - diagnosis Arthritis, Rheumatoid - drug therapy Arthritis, Rheumatoid - genetics Biomarkers DNA methylation Epigenome Humans Immunology machine learning rheumatoid arthritis therapy response Tumor Necrosis Factor-alpha DNA methylation machine learning rheumatoid arthritis therapy response adalimumab
ISSN:	1664-3224, 1664-3224
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!